BRPI0717769A2 - Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio - Google Patents

Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio

Info

Publication number
BRPI0717769A2
BRPI0717769A2 BRPI0717769A BRPI0717769A2 BR PI0717769 A2 BRPI0717769 A2 BR PI0717769A2 BR PI0717769 A BRPI0717769 A BR PI0717769A BR PI0717769 A2 BRPI0717769 A2 BR PI0717769A2
Authority
BR
Brazil
Prior art keywords
osteoarthritis
treatment
gel formulation
individual suffering
sodium diclofenac
Prior art date
Application number
Other languages
English (en)
Portuguese (pt)
Inventor
Ed Kisak
Jagat Singh
Original Assignee
Nuvo Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39023542&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0717769(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nuvo Res filed Critical Nuvo Res
Publication of BRPI0717769A2 publication Critical patent/BRPI0717769A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
BRPI0717769 2006-10-17 2007-10-17 Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio BRPI0717769A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82975606P 2006-10-17 2006-10-17
PCT/US2007/081674 WO2008049020A2 (en) 2006-10-17 2007-10-17 Diclofenac gel

Publications (1)

Publication Number Publication Date
BRPI0717769A2 true BRPI0717769A2 (pt) 2013-11-05

Family

ID=39023542

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0717769 BRPI0717769A2 (pt) 2006-10-17 2007-10-17 Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio

Country Status (14)

Country Link
US (14) US8252838B2 (OSRAM)
EP (2) EP2086504B1 (OSRAM)
JP (1) JP5432716B2 (OSRAM)
CN (2) CN101588791A (OSRAM)
AU (1) AU2007311019B2 (OSRAM)
BR (1) BRPI0717769A2 (OSRAM)
CA (1) CA2666398C (OSRAM)
DK (1) DK2086504T3 (OSRAM)
IL (1) IL198161A (OSRAM)
MX (1) MX2009004038A (OSRAM)
NZ (1) NZ577020A (OSRAM)
RU (1) RU2463038C2 (OSRAM)
WO (1) WO2008049020A2 (OSRAM)
ZA (1) ZA200903135B (OSRAM)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8480797B2 (en) 2005-09-12 2013-07-09 Abela Pharmaceuticals, Inc. Activated carbon systems for facilitating use of dimethyl sulfoxide (DMSO) by removal of same, related compounds, or associated odors
WO2007033180A1 (en) 2005-09-12 2007-03-22 Abela Pharmaceuticals, Inc. Materials for facilitating administration of dimethyl sulfoxide (dmso) and related compounds
EP1937286B1 (en) 2005-09-12 2016-03-09 Abela Pharmaceuticals, Inc. Compositions comprising dimethyl sulfoxide (dmso)
AU2006291134C1 (en) 2005-09-12 2013-08-15 Abela Pharmaceuticals, Inc. Systems for removing dimethyl sulfoxide (DMSO) or related compounds, or odors associated with same
BRPI0717769A2 (pt) 2006-10-17 2013-11-05 Nuvo Res Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio
US20100100060A1 (en) * 2008-10-17 2010-04-22 Novartis Ag Applicator for pharmaceutical product and method of using same
BRPI0921494A2 (pt) 2008-11-03 2018-10-30 Prad Reasearch And Development Ltd método de planejamento de uma operação de amostragem para uma formação subterrãnea, método de contolar uma operação de amostragem de formação subterrânea, método de controlar uma operação de perfuração para uma formação subterrãnea, e método de realizar uma amostragem durante a operação de perfuração.
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
US8546450B1 (en) 2009-03-31 2013-10-01 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
EP2482850A2 (en) * 2009-09-30 2012-08-08 Nuvo Research Inc. Topical formulations
EP2485730A1 (en) 2009-10-09 2012-08-15 Nuvo Research Inc. Topical formulation comprising etoricoxib and a zwitterionic surfactant
US9855212B2 (en) 2009-10-30 2018-01-02 Abela Pharmaceuticals, Inc. Dimethyl sulfoxide (DMSO) or DMSO and methylsulfonylmethane (MSM) formulations to treat infectious diseases
WO2011060195A2 (en) 2009-11-11 2011-05-19 Nuvo Research Inc. Topical eutectic formulation
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
EP2544662B1 (en) 2010-03-10 2020-05-20 Nuvo Pharmaceuticals Inc. Foamable formulation
WO2011149645A1 (en) 2010-05-28 2011-12-01 Nuvo Research Inc. Topical etoricoxib formulation
KR20140027319A (ko) * 2011-05-26 2014-03-06 노파르티스 아게 생리학상 활성제의 경피 투여를 위한 조성물
US10813897B2 (en) * 2011-12-27 2020-10-27 Cmpd Licensing, Llc Composition and method for compounded therapy
CN102525886B (zh) * 2012-01-13 2013-03-13 湖北科益药业股份有限公司 双氯芬酸二乙胺乳胶剂及其制备方法
FR2990134B1 (fr) * 2012-05-07 2014-11-21 Anaconda Pharma Composition pharmaceutique d'un inhibiteur du virus du papillome
US8853189B2 (en) 2012-05-31 2014-10-07 Prima Innovations, Llc Antispasmodic 1,2-Diols and 1,2,3-triols
ITMI20121205A1 (it) 2012-07-11 2014-01-12 Glycores 2000 Srl Composizione con attivita' antinfiammatoria ed analgesica da somministrare per uso esterno mediante vaporizzazione
US20140113970A1 (en) * 2012-10-22 2014-04-24 Mallinckrodt LLC Covidien Dispensing system
EP2742932A1 (en) * 2012-12-17 2014-06-18 Laboratorios Ojer Pharma S.L. Gel compositions
US9144553B2 (en) 2012-12-21 2015-09-29 Teikoku Pharma Usa, Inc. Compositions and methods for transdermal delivery of hormones and other medicinal agents
US9012402B1 (en) 2014-06-11 2015-04-21 James Blanchard Gel for topical delivery of NSAIDs to provide relief of musculoskeletal pain and methods for its preparation
RU2711090C2 (ru) * 2015-01-23 2020-01-15 Др. Редди'С Лабораториз Лимитед Неокрашивающая гелевая композиция, содержащая нимесулид, для местного применения
US10716754B2 (en) 2016-03-28 2020-07-21 Tioga Research, Inc. Topical formulation
EA038882B1 (ru) * 2016-03-30 2021-11-02 Сарудбхава Формулатионс Приват Лимитед Фармацевтическая композиция апремиласта
KR20190003535A (ko) 2016-03-31 2019-01-09 스마테크 토피칼, 인코포레이티드 전달 시스템
IT201700009711A1 (it) * 2017-01-30 2018-07-30 Applied Pharma Res Sodium free Diclofenac potassium oral solutions Soluzioni orali di Diclofenac potassico prive di sodio
US20200009157A1 (en) * 2017-02-28 2020-01-09 John W. Backer Dimethyl sulfoxide (dmso) and hydrocortisone compositions and methods of use
US10821075B1 (en) 2017-07-12 2020-11-03 James Blanchard Compositions for topical application of a medicaments onto a mammalian body surface
JP7546297B2 (ja) 2018-11-20 2024-09-06 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのチエニル－アニリン化合物
CA3120371A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Cyanoaryl-aniline compounds for treatment of dermal disorders
WO2020106304A1 (en) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Topical formulations
CN113473986B (zh) 2018-11-20 2024-10-11 恩福莱克逊治疗有限公司 用于治疗皮肤疾病萘啶酮苯胺化合物
WO2021061913A1 (en) * 2019-09-27 2021-04-01 Encube Ethicals, Pvt. Ltd. Diclofenac sodium topical solution
AU2020379828A1 (en) 2019-11-06 2022-04-28 Smartech Topical, Inc. Topical formulations of cyclooxygenase inhibitors and their use
CN110687229A (zh) * 2019-11-12 2020-01-14 山东省药学科学院 一种双氯芬酸钠原料及其制剂中有关物质的分析方法
US12324854B2 (en) 2020-08-26 2025-06-10 Canadian Nano Pharmaceutical Technology Inc. Nano-emulsion based compositions, methods for their preparation and their use in delivery of active ingredients
WO2022055927A1 (en) * 2020-09-11 2022-03-17 Ps Therapy Ltd. Topical compositions and methods of use
KR20240125577A (ko) 2021-11-23 2024-08-19 엔플렉션 테라퓨틱스, 인코포레이티드 피롤로피리딘-아닐린 화합물의 제형
CN114259461B (zh) * 2021-11-29 2023-09-12 海南全星制药有限公司 一种双氯芬酸钠凝胶及其制备方法
EP4499036A1 (en) 2022-03-25 2025-02-05 Glycores 2000 srl Topical pharmaceutical composition with anti-inflammatory and analgesic activity and uses thereof
CN116869976A (zh) * 2023-09-07 2023-10-13 晶易医药科技(成都)有限公司 双氯芬酸二乙胺凝胶贴膏组合物、凝胶贴膏及其制备方法

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342784A (en) * 1964-10-06 1982-08-03 E. R. Squibb & Sons, Inc. Chemical compositions and method of utilization
US3740421A (en) * 1966-09-19 1973-06-19 Basf Wyandotte Corp Polyoxyethylene-polyoxypropylene aqueous gels
US3740420A (en) 1967-11-28 1973-06-19 Crown Zellerbach Corp Pharmaceutical compositions with dimethyl sulfoxide
US3711602A (en) 1970-10-30 1973-01-16 Crown Zellerbach Corp Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso
GB2023000B (en) 1978-06-17 1982-10-13 Kowa Co Antinflammatory analgesic gelled ointments
US4296104A (en) 1979-08-30 1981-10-20 Herschler R J Therapeutic dimethyl sulfoxide composition and methods of use
US4441739A (en) * 1981-08-27 1984-04-10 Cluff Warren S Booklet
US4543251A (en) 1983-12-09 1985-09-24 Toko Yakuhin Industry Co., Ltd. Gel preparations for external application
US4670254A (en) 1983-12-09 1987-06-02 Toko Yakuhin Industry Co., Ltd. Gel preparations for topical application of diclofenac sodium
CA1236029A (en) * 1984-05-14 1988-05-03 Edmund Sandborn Pharmaceutical solutions comprising dimethyl sulfoxide
JPS61254519A (ja) * 1985-05-07 1986-11-12 Nitto Electric Ind Co Ltd ゲル状医薬製剤
JPS61277613A (ja) * 1985-05-31 1986-12-08 Nitto Electric Ind Co Ltd ゲル状外用医薬組成物
US4707354A (en) 1985-06-17 1987-11-17 Alpen Tau, Inc. Mature skin treatment and protectant compositions and methods of using same
JPH06104624B2 (ja) * 1986-05-07 1994-12-21 太郎 小木曽 経皮吸収剤
DE3632359A1 (de) * 1986-09-24 1988-04-07 Troponwerke Gmbh & Co Kg Arzneimittelzubereitungen
US4855294A (en) * 1988-09-06 1989-08-08 Theratech, Inc. Method for reducing skin irritation associated with drug/penetration enhancer compositions
US5215739A (en) 1989-04-05 1993-06-01 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
DK0450123T3 (da) * 1990-04-05 1995-08-21 Knoll Ag Farmaceutisk præparat til topisk administration indeholdende dichlofenac-natrium
US5350769A (en) * 1990-10-30 1994-09-27 Ss Pharmaceutical Co., Ltd. Antiinflammatory gel preparation
US5674912A (en) 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5874479A (en) 1991-03-01 1999-02-23 Warner-Lambert Company Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same
EP0592569A1 (en) * 1991-07-03 1994-04-20 Sano Corporation Composition and method for transdermal delivery of diclofenac
IL101387A (en) 1992-03-26 1999-11-30 Pharmos Ltd Emulsion with enhanced topical and/or transdermal systemic effect utilizing submicron oil droplets
JP2523428B2 (ja) 1992-12-04 1996-08-07 エスエス製薬株式会社 消炎鎮痛ゲル製剤
DE4313402A1 (de) 1993-04-23 1994-10-27 Hexal Pharma Gmbh Transdermale Wirkstoffzubereitung
JPH11513393A (ja) * 1995-10-12 1999-11-16 ジーエス ディベロップメント エービー 皮膚又は粘膜表面へのもしくは介する活性物質の投与用医薬組成物
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
JP3291222B2 (ja) 1997-05-19 2002-06-10 トヨタ自動車株式会社 軟質光輝化製品
US5976566A (en) * 1997-08-29 1999-11-02 Macrochem Corporation Non-steroidal antiinflammtory drug formulations for topical application to the skin
US6399093B1 (en) 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
US6962691B1 (en) 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
KR100433614B1 (ko) 2000-06-16 2004-05-31 주식회사 태평양 친수성 또는 염의 형태로 된 약물을 함유하는 경피흡수제제
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
JP2004532871A (ja) 2001-05-31 2004-10-28 ファルマシア・コーポレーション 皮膚浸透性シクロオキシゲナーゼ−２選択的阻害組成物
US6858200B2 (en) 2001-06-06 2005-02-22 Schering-Plough Healthcare Healthcare Products Inc. Sunscreen formulations
US6750291B2 (en) 2002-04-12 2004-06-15 Pacific Corporation Film-forming agent for drug delivery and preparation for percutaneous administration containing the same
ITMI20020986A1 (it) 2002-05-10 2003-11-10 Acraf Composizione a base di diclofenac per il trattamento topico di affezioni del cavo orofaringeo
PE20040321A1 (es) * 2002-08-22 2004-07-15 Novartis Consumer Health Sa Composicion topica que comprende diclofenaco
US7138394B2 (en) 2002-09-27 2006-11-21 Alpharx Inc. Vehicle for topical delivery of anti-inflammatory compounds
US20040175415A1 (en) 2003-03-05 2004-09-09 Chan Alvin C. Formulations and methods of delivery of intact tocopheryl succinate to humans
US20040222123A1 (en) 2003-05-06 2004-11-11 Barr Laboratories, Inc. Kit for pharmaceuticals
WO2005009510A2 (en) * 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
DE20319986U1 (de) 2003-12-23 2004-04-15 Merckle Gmbh Chemisch Pharmazeutische Fabrik Topische Zubereitungen enthaltend Dimethylsulfoxid und Dexpanthenol
US8252314B2 (en) 2004-09-24 2012-08-28 Hill's Pet Nutrition, Inc. Hypoallergenic composition
EA200701131A1 (ru) 2004-11-24 2007-12-28 Алгоркс Фармасьютикалз, Инк. Гелеобразная препаративная форма капсаициноида и способы её применения
GT200600046A (es) * 2005-02-09 2006-09-25 Terapia de combinacion
US20070053984A1 (en) 2005-03-03 2007-03-08 Monique Spann-Wade Topical gels compositions
EP1858503B1 (en) * 2005-03-03 2013-09-04 Green, Monique Renata Topical gels compositions
WO2007010559A2 (en) 2005-07-20 2007-01-25 Panacea Biotec Ltd. Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
EP1909772A4 (en) 2005-08-05 2011-07-13 Nuvo Res Inc TRANSDERMAL DRUG FORMULATION
US20070141182A1 (en) 2005-12-20 2007-06-21 Niazi Sarfaraz K Combination of multiple nonteroidal antiinflammatory drugs and muscle relaxants for local treatment of musculoskeletal pain
EP1999626A4 (en) 2006-01-26 2009-11-25 Combinatorx Inc METHODS, COMPOSITIONS AND NEEDS FOR TREATING MUSCULOSKELETAL DISORDERS AND SYMPTOMS ASSOCIATED THEREWITH
US20070280972A1 (en) * 2006-04-25 2007-12-06 Zars, Inc. Adhesive solid gel-forming formulations for dermal drug delivery
BRPI0717769A2 (pt) 2006-10-17 2013-11-05 Nuvo Res Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio
WO2008088827A2 (en) 2007-01-16 2008-07-24 Tyratech, Inc. Pest control compositions and methods
BRPI0921654A2 (pt) 2008-11-28 2016-02-10 Advance Holdings Ltd formulação farmacêutica
US8618164B2 (en) 2009-03-31 2013-12-31 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
US8546450B1 (en) 2009-03-31 2013-10-01 Nuvo Research Inc. Treatment of pain with topical diclofenac compounds
US20140113970A1 (en) 2012-10-22 2014-04-24 Mallinckrodt LLC Covidien Dispensing system

Also Published As

Publication number Publication date
US9220784B2 (en) 2015-12-29
US9339551B2 (en) 2016-05-17
CN104606126A (zh) 2015-05-13
US20140018427A1 (en) 2014-01-16
US9168305B2 (en) 2015-10-27
US20150126607A1 (en) 2015-05-07
EP2626063B1 (en) 2022-03-16
US20150011635A1 (en) 2015-01-08
JP5432716B2 (ja) 2014-03-05
IL198161A0 (en) 2009-12-24
EP2086504A2 (en) 2009-08-12
US20200237919A1 (en) 2020-07-30
US9168304B2 (en) 2015-10-27
US20150231264A1 (en) 2015-08-20
US20150313998A1 (en) 2015-11-05
HK1134024A1 (en) 2010-04-16
US9539335B2 (en) 2017-01-10
DK2086504T3 (da) 2014-04-07
US9101591B2 (en) 2015-08-11
US8563613B2 (en) 2013-10-22
CN101588791A (zh) 2009-11-25
EP2626063A1 (en) 2013-08-14
US9066913B2 (en) 2015-06-30
WO2008049020A2 (en) 2008-04-24
US20160213784A1 (en) 2016-07-28
JP2010506952A (ja) 2010-03-04
US20150126606A1 (en) 2015-05-07
US8252838B2 (en) 2012-08-28
WO2008049020A3 (en) 2008-06-12
US20080300311A1 (en) 2008-12-04
AU2007311019A8 (en) 2009-06-18
US8871809B2 (en) 2014-10-28
NZ577020A (en) 2012-05-25
IL198161A (en) 2015-09-24
AU2007311019A1 (en) 2008-04-24
EP2086504B1 (en) 2014-01-08
ZA200903135B (en) 2010-08-25
US20150231262A1 (en) 2015-08-20
CA2666398A1 (en) 2008-04-24
US20170266296A1 (en) 2017-09-21
US20120295978A1 (en) 2012-11-22
RU2463038C2 (ru) 2012-10-10
US20160045605A1 (en) 2016-02-18
MX2009004038A (es) 2009-08-24
RU2009118392A (ru) 2010-11-27
US20150231263A1 (en) 2015-08-20
AU2007311019B2 (en) 2013-05-16
US9339552B2 (en) 2016-05-17
CA2666398C (en) 2015-08-18

Similar Documents

Publication Publication Date Title
BRPI0717769A2 (pt) Formulação de gel, método para o tratamento da osteoartrite em um indivíduo sofrendo de dor articular, e, uso de diclofenac de sódio
IL274602A (en) Pharmaceutical tablets containing eltrombopag olamine, methods for their preparation and use thereof in the preparation of medicaments for treating thrombocytopenia
EP2114419B8 (en) Sodium meta arsenite for use in the treatment of pain and inflammation
BRPI0914902A2 (pt) composição farmacêutica e método para tratamento de mal de parkinson
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
PL2803663T3 (pl) Inhibitory ludzkiej białkowej fosfatazy tyrozynowej i ich zastosowanie farmaceutyczne
BRPI0510043A (pt) método de tratamento de dor neuropática usando antagonista de receptor crth2
BRPI0810354A2 (pt) Composto, uso de um composto, composição farmacêutica, e, método de tratamento de um dispositivo de dor
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI0717149A2 (pt) Composição oral contendo redes de gel e processo para o preparo da mesma
DK2097116T3 (da) In situ system til intraartikulær brusk- og knoglevævsopheling
BRPI0717454A2 (pt) Dispositivos implantáveis para o tratamento de incontinência e métodos para o uso dos mesmos
BR112013014583A2 (pt) composição farmacêutica, e, métodos para o tratamento de inflamação, para o tratamento da dor, e para preparar 3-metanossulfonilpropionitrila
BRPI0812502A2 (pt) Método e aparelho para tratamento de tecido por ultrassom
BRPI0816214A2 (pt) Uso cosmético, composição cosmética e/ou dermatológica, e, métodos para o tratamento cosmético da pele, para o tratamento cosmético de sinais cutâneos de envelhecimento e/ou fotoenvelhecimento e para o tratamento cosmético para prevenir e/ou tratar substâncias queratinosas secas
HRP20190059T1 (hr) Pripravci za liječenje boli i/ili upale
BRPI0821080A2 (pt) Composições de gel de polissacarídeo e métodos para liberação sustentada de fármacos
BRPI0820212A2 (pt) Dispositivo para tratamento de fraturas, método para tratamento de fraturas, e, kit para tratamento de fraturas
BR112012022211A2 (pt) composto. composição farmacêutica, método de tratamento de uma doença meidada por h4r, método de inibição de h4h, método de tratamento da dor ou inflamação resultante de cirurgia de catarata, método para atingir um efeito em um paciente e uso de uma composto
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0607198A2 (pt) composição, uso da composição método de tratamento doenças, e, embalagem farmacêutica
BRPI1010861A2 (pt) métodos para tratamento de dor, inflamação ou osteoartrite, pacote e formulação farmacêutica
BRPI0715014A2 (pt) Método e dispositivo para o tratamento de recipientes
BRPI0917189A2 (pt) dispositivo para uso em tratamento cirúrgico de tórax em funil e método de tratamento.
BRPI0816097A2 (pt) composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: NUVO RESEARCH INC. (CA)

B25D Requested change of name of applicant approved

Owner name: NUVO PHARMACEUTICALS INC. (CA)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements